WallStreetZenWallStreetZen

NASDAQ: PRLD
Prelude Therapeutics Inc Earnings & Revenue

OverviewForecastEarnings
DividendOwnership

PRLD earnings and revenue history

Current Revenue
$0.0
Current Earnings
-$121.8M
Current Profit Margin
0%

PRLD Return on Equity

Current Company
-53.4%
Current Industry
-63.5%
Current Market
188%
PRLD's Return on Equity (-53.4%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when PRLD announces earnings.

PRLD Return on Assets

Current Company
-48%
Current Industry
2.9%
PRLD is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

PRLD Return on Capital Employed

Current Company
-47.62%
Current Industry
19.5%
PRLD's ability to generate Return... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

PRLD vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
PRLD$0.00-$118.73M-$121.83MN/AN/A
MACK$0.00-$1.17M-$1.18MN/AN/A
ADVM$3.60M-$99.57M-$117.17M+17.43%N/A
ACRV$0.00-$59.07M-$60.39MN/AN/A
XFOR$0.00-$93.32M-$101.17M-100.00%N/A
View Top Biotech Stocks

PRLD earnings dates

Next earnings date
May 6, 2024

Prelude Therapeutics Earnings & Revenue FAQ

What were PRLD's earnings last quarter?

On Invalid Date, Prelude Therapeutics (NASDAQ: PRLD) reported Q4 2023 earnings per share (EPS) of -$0.47, up 21.67% year over year. Total Prelude Therapeutics earnings for the quarter were -$33.08 million. In the same quarter last year, Prelude Therapeutics's earnings per share (EPS) was -$0.60.

If you're new to stock investing, here's how to buy Prelude Therapeutics stock.

What was PRLD's earnings growth in the past year?

As of Q2 2024, Prelude Therapeutics's earnings has grown year over year. Prelude Therapeutics's earnings in the past year totalled -$121.83 million.

What is PRLD's earnings date?

Prelude Therapeutics's earnings date is Invalid Date. Add PRLD to your watchlist to be reminded of PRLD's next earnings announcement.

What was PRLD's revenue last quarter?

On Invalid Date, Prelude Therapeutics (NASDAQ: PRLD) reported Q4 2023 revenue of $0.00 up N/A year over year. In the same quarter last year, Prelude Therapeutics's revenue was $0.00.

What was PRLD's revenue growth in the past year?

As of Q2 2024, Prelude Therapeutics's revenue has grown null year over year. Prelude Therapeutics's revenue in the past year totalled $0.00.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.